REVIVA PHARMACEUTICALS HOLDINGS CEO Laxminarayan Bhat's 2023 pay jumps 394% to $2.8M
REVIVA PHARMACEUTICALS HOLDINGS reports 2023 executive compensation
By ExecPay News
Published: October 28, 2024
REVIVA PHARMACEUTICALS HOLDINGS reported fiscal year 2023 executive compensation information on October 28, 2024.
In 2023, two executives at REVIVA PHARMACEUTICALS HOLDINGS received on average a compensation package of $2M, a 356% increase compared to previous year.
Average pay of disclosed executives at REVIVA PHARMACEUTICALS HOLDINGS
Laxminarayan Bhat, Chief Executive Officer, received $2.8M in total, which increased by 394% compared to 2022. 78% of Bhat's compensation, or $2.2M, was in option awards. Bhat also received $158K in non-equity incentive plan and $450K in salary.
Narayan Prabhu, Chief Financial Officer, received a compensation package of $1.2M, which increased by 203% compared to previous year. 66% of the compensation package, or $828K, was in option awards.
Related executives
You may also like
Source: SEC filing on October 28, 2024.